Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Bayer's new CETP inhibitors described in recently published patent

May 17, 1999

New vitronectin receptor ligands emerge from collaborative research at HMR and Genentech

May 17, 1999

Vitronectin receptor antagonists from SB for osteoporosis, cancer, etc.

May 14, 1999

Cholesteryl ester transfer protein inhibitors patented by Bayer

May 14, 1999

Roberts will distribute emergency contraceptive kit in Canada

May 14, 1999

Chromium picolinate identified as insulin assistance factor

May 14, 1999

New benzazepine compound selectively inhibits vitronectin receptors

May 13, 1999

CETP inhibitors in the Bayer pipeline

May 13, 1999

Duramed's conjugated estrogens now available in U.S.

May 13, 1999

New class of CETP inhibitors useful for lipid disorders and coronary artery disease

May 12, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...